Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068366885> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W2068366885 endingPage "370" @default.
- W2068366885 startingPage "363" @default.
- W2068366885 abstract "The purpose of the study was to evaluate the feasibility of increasing dose intensity by a stepwise reduction of the time intervals between chemotherapy cycles in separate patient cohorts with small-cell lung cancer. Patients received up to 6 courses of combination chemotherapy with carboplatin, etoposide, ifosfamide and vincristine followed by support with filgrastim. Dose intensity, incidence, duration and severity of neutropenic fever and infections, objective response to chemotherapy, and safety of filgrastim were determined.29 patients with small-cell lung cancer (limited disease: 2, extensive disease: 27) were treated with a combination of carboplatin 250 mg/m2 i.v. day 1, ifosfamide 2 g/m2 and etoposide 120 mg/m2 i.v. days 1 and 2, etoposide 120 mg/m2 orally day 3, and vincristine 1.4 mg/m2 day 14. Initially, filgrastim (5 micrograms/kg) was administered subcutaneously from day 7 to 16. With shorter treatment intervals, filgrastim was administered on days 4-16 or 4-14.An overall increase in dose intensity by a factor of 1.44 was achieved after reducing the treatment interval from 27 to 17 days. Further reduction to 14 days was not feasible due to persistent thrombocytopenia. Six patients (21%) developed a total of 9 febrile episodes, and 14 patients (48%) had to be withdrawn from the study before the completion of six cycles of chemotherapy. The median duration of infectious episodes was 6 days. Overall, a total of 22 of 27 evaluable patients had an objective response. Longer treatment intervals resulted in a lower probability for objective response (> or = 23 days: 10/14 patients vs. < or = 17 days: 7/7 patients).Filgrastim allows for the reduction of treatment intervals in patients with small-cell lung cancer and increased dose intensity with acceptable hematologic and nonhematologic toxicities." @default.
- W2068366885 created "2016-06-24" @default.
- W2068366885 creator A5010943768 @default.
- W2068366885 creator A5011557387 @default.
- W2068366885 creator A5011713808 @default.
- W2068366885 creator A5011818102 @default.
- W2068366885 creator A5014774628 @default.
- W2068366885 creator A5025105470 @default.
- W2068366885 creator A5029594523 @default.
- W2068366885 creator A5055388299 @default.
- W2068366885 creator A5064304355 @default.
- W2068366885 creator A5071485689 @default.
- W2068366885 creator A5077174632 @default.
- W2068366885 creator A5091279370 @default.
- W2068366885 date "1997-01-01" @default.
- W2068366885 modified "2023-09-24" @default.
- W2068366885 title "Dose Intensity Phase l/lI Trial with Carboplatin, Ifosfamide, Etoposide and Vincristine Combined with Filgrastim in Patients with Small-Cell Lung Cancer" @default.
- W2068366885 doi "https://doi.org/10.1159/000227719" @default.
- W2068366885 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9260596" @default.
- W2068366885 hasPublicationYear "1997" @default.
- W2068366885 type Work @default.
- W2068366885 sameAs 2068366885 @default.
- W2068366885 citedByCount "5" @default.
- W2068366885 countsByYear W20683668852016 @default.
- W2068366885 crossrefType "journal-article" @default.
- W2068366885 hasAuthorship W2068366885A5010943768 @default.
- W2068366885 hasAuthorship W2068366885A5011557387 @default.
- W2068366885 hasAuthorship W2068366885A5011713808 @default.
- W2068366885 hasAuthorship W2068366885A5011818102 @default.
- W2068366885 hasAuthorship W2068366885A5014774628 @default.
- W2068366885 hasAuthorship W2068366885A5025105470 @default.
- W2068366885 hasAuthorship W2068366885A5029594523 @default.
- W2068366885 hasAuthorship W2068366885A5055388299 @default.
- W2068366885 hasAuthorship W2068366885A5064304355 @default.
- W2068366885 hasAuthorship W2068366885A5071485689 @default.
- W2068366885 hasAuthorship W2068366885A5077174632 @default.
- W2068366885 hasAuthorship W2068366885A5091279370 @default.
- W2068366885 hasConcept C126322002 @default.
- W2068366885 hasConcept C126894567 @default.
- W2068366885 hasConcept C141071460 @default.
- W2068366885 hasConcept C2776256026 @default.
- W2068366885 hasConcept C2776694085 @default.
- W2068366885 hasConcept C2776755627 @default.
- W2068366885 hasConcept C2777506904 @default.
- W2068366885 hasConcept C2777767877 @default.
- W2068366885 hasConcept C2778119113 @default.
- W2068366885 hasConcept C2778239845 @default.
- W2068366885 hasConcept C2779171977 @default.
- W2068366885 hasConcept C2779429289 @default.
- W2068366885 hasConcept C2781451048 @default.
- W2068366885 hasConcept C71924100 @default.
- W2068366885 hasConceptScore W2068366885C126322002 @default.
- W2068366885 hasConceptScore W2068366885C126894567 @default.
- W2068366885 hasConceptScore W2068366885C141071460 @default.
- W2068366885 hasConceptScore W2068366885C2776256026 @default.
- W2068366885 hasConceptScore W2068366885C2776694085 @default.
- W2068366885 hasConceptScore W2068366885C2776755627 @default.
- W2068366885 hasConceptScore W2068366885C2777506904 @default.
- W2068366885 hasConceptScore W2068366885C2777767877 @default.
- W2068366885 hasConceptScore W2068366885C2778119113 @default.
- W2068366885 hasConceptScore W2068366885C2778239845 @default.
- W2068366885 hasConceptScore W2068366885C2779171977 @default.
- W2068366885 hasConceptScore W2068366885C2779429289 @default.
- W2068366885 hasConceptScore W2068366885C2781451048 @default.
- W2068366885 hasConceptScore W2068366885C71924100 @default.
- W2068366885 hasIssue "5" @default.
- W2068366885 hasLocation W20683668851 @default.
- W2068366885 hasLocation W20683668852 @default.
- W2068366885 hasOpenAccess W2068366885 @default.
- W2068366885 hasPrimaryLocation W20683668851 @default.
- W2068366885 hasRelatedWork W157045520 @default.
- W2068366885 hasRelatedWork W1988562881 @default.
- W2068366885 hasRelatedWork W2006037071 @default.
- W2068366885 hasRelatedWork W2026047582 @default.
- W2068366885 hasRelatedWork W2026834862 @default.
- W2068366885 hasRelatedWork W2035589037 @default.
- W2068366885 hasRelatedWork W2045065111 @default.
- W2068366885 hasRelatedWork W2054697909 @default.
- W2068366885 hasRelatedWork W2068366885 @default.
- W2068366885 hasRelatedWork W2079019563 @default.
- W2068366885 hasVolume "54" @default.
- W2068366885 isParatext "false" @default.
- W2068366885 isRetracted "false" @default.
- W2068366885 magId "2068366885" @default.
- W2068366885 workType "article" @default.